July 2020 - Evolution Biotechnologies
archive,date,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Bedford, UK, July 20th 2020 Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company pioneering the use of biological control to benefit human health, today reports that it has completed the registration process and has been listed on Oxford Business Network’s OBN Ventures Investment Platform at https://obn.envestry.com/. Dr. David Harper, CEO of Evolution, said: “this is an important step forward in today’s difficult market, and we look forward to working with OBN Ventures to present this opportunity to a new group of investors”. About OBN Ventures: OBN Ventures Ltd (OBNV) is a wholly owned subsidiary of OBN (UK) Ltd, and offers a sophisticated FCA-approved on-line investment platform...